Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and VIVUS (OTCMKTS:VVUSQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Sienna Biopharmaceuticals and VIVUS, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Sienna Biopharmaceuticals | 0 | 0 | 0 | 0 | N/A |
VIVUS | 0 | 0 | 0 | 0 | N/A |
Risk and Volatility
Sienna Biopharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, VIVUS has a beta of -3.25, meaning that its share price is 425% less volatile than the S&P 500.
Earnings and Valuation
This table compares Sienna Biopharmaceuticals and VIVUS's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Sienna Biopharmaceuticals | N/A | N/A | $-73,470,000.00 | N/A | N/A |
VIVUS | $69.76 million | 0.03 | $-31,500,000.00 | ($2.96) | -0.04 |
VIVUS has higher revenue and earnings than Sienna Biopharmaceuticals.
Profitability
This table compares Sienna Biopharmaceuticals and VIVUS's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Sienna Biopharmaceuticals | N/A | N/A | N/A |
VIVUS | -39.28% | N/A | -12.18% |
Institutional and Insider Ownership
7.3% of VIVUS shares are owned by institutional investors. 27.2% of Sienna Biopharmaceuticals shares are owned by company insiders. Comparatively, 12.0% of VIVUS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Sienna Biopharmaceuticals beats VIVUS on 4 of the 7 factors compared between the two stocks.